As previously reported, BofA analyst Jason Zemansky downgraded Esperion to Underperform from Neutral with a price target of $1.50, down from $8, after the company disclosed that partner Daiichi Sankyo Europe disagreed with the company’s entitlement to a $300M milestone related to bempedoic acid. It remains unclear how, and how quickly, the dispute will play out, which adds to uncertainties facing the company, "not the least of which" is the potential to seek out additional funds from "an arguably skeptical investor base," the analyst tells investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ESPR:
- Esperion Tanks after Dispute with Daiichi Sankyo
- Esperion reports disagreement with Daiichi Sankyo over milestone payments
- Esperion says ILEP recommends use of bempedoic acid ahead of PCSK9 inhibitors
- Esperion upgraded to Neutral from Underperform at Credit Suisse
- Esperion Tanks on Nexletol Cardiovascular Data